286 related articles for article (PubMed ID: 32444560)
1. Detection and Assessment of α-Synuclein Oligomers in the Urine of Parkinson's Disease Patients.
Nam D; Lee JY; Lee M; Kim J; Seol W; Son I; Ho DH
J Parkinsons Dis; 2020; 10(3):981-991. PubMed ID: 32444560
[TBL] [Abstract][Full Text] [Related]
2. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
[TBL] [Abstract][Full Text] [Related]
3. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
[TBL] [Abstract][Full Text] [Related]
4. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
[TBL] [Abstract][Full Text] [Related]
5. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
[TBL] [Abstract][Full Text] [Related]
6. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease.
Wang X; Yu S; Li F; Feng T
Neurosci Lett; 2015 Jul; 599():115-9. PubMed ID: 25998655
[TBL] [Abstract][Full Text] [Related]
7. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
[TBL] [Abstract][Full Text] [Related]
8. α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease.
Cao Z; Wu Y; Liu G; Jiang Y; Wang X; Wang Z; Feng T
Neurosci Lett; 2019 Mar; 696():114-120. PubMed ID: 30579996
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's and Lewy body dementia CSF biomarkers.
Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
[TBL] [Abstract][Full Text] [Related]
10. Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease.
Vivacqua G; Latorre A; Suppa A; Nardi M; Pietracupa S; Mancinelli R; Fabbrini G; Colosimo C; Gaudio E; Berardelli A
PLoS One; 2016; 11(3):e0151156. PubMed ID: 27011009
[TBL] [Abstract][Full Text] [Related]
11. Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
Vivacqua G; Suppa A; Mancinelli R; Belvisi D; Fabbrini A; Costanzo M; Formica A; Onori P; Fabbrini G; Berardelli A
Parkinsonism Relat Disord; 2019 Jun; 63():143-148. PubMed ID: 30796010
[TBL] [Abstract][Full Text] [Related]
12. Analysis of α-synuclein levels related to LRRK2 kinase activity: from substantia nigra to urine of patients with Parkinson's disease.
Nam D; Kim A; Han SJ; Lee SI; Park SH; Seol W; Son I; Ho DH
Anim Cells Syst (Seoul); 2021 Feb; 25(1):28-36. PubMed ID: 33717414
[TBL] [Abstract][Full Text] [Related]
13. Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference.
Ishii R; Tokuda T; Tatebe H; Ohmichi T; Kasai T; Nakagawa M; Mizuno T; El-Agnaf OM
PLoS One; 2015; 10(4):e0123162. PubMed ID: 25849645
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
15. Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review.
Bougea A; Koros C; Stefanis L
J Neural Transm (Vienna); 2019 Nov; 126(11):1373-1382. PubMed ID: 31401695
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of α-synuclein oligomers using formaldehyde.
Ruesink H; Reimer L; Gregersen E; Moeller A; Betzer C; Jensen PH
PLoS One; 2019; 14(10):e0216764. PubMed ID: 31603909
[TBL] [Abstract][Full Text] [Related]
17. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
[TBL] [Abstract][Full Text] [Related]
18. Total α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA.
Abd-Elhadi S; Basora M; Vilas D; Tolosa E; Sharon R
Anal Bioanal Chem; 2016 Nov; 408(27):7669-7677. PubMed ID: 27624766
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
[TBL] [Abstract][Full Text] [Related]
20. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
